Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants

Cell Reports

Volumn 6, Issue 4, 2014, Pages 657-669

  An, Jian ^a,b   Wang, Chenji ^a   Deng, Yibin ^c   Yu, Long ^a   Huang, Haojie ^b,d,e  

^a FUDAN UNIVERSITY   (China)

^b MAYO GRADUATE SCHOOL   (United States)

^c University of Minnesota Hormel Institute   (United States)

^d Mayo Clinic   (United States)

^e MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ENZALUTAMIDE; MESSENGER RNA; MIBOLERONE; UBIQUITIN PROTEIN LIGASE E3; CELL PROTEIN; CULLIN; CULLIN 3; PROTEASOME; RBX1 PROTEIN; SERINE; SPOP PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE INTERACTION; GENE MUTATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPOP GENE; UBIQUITINATION; CANCER INHIBITION; GENE; GENE EXPRESSION REGULATION; HINGE REGION; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PSA GENE; TMPRSS2 GENE; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; BINDING SITES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEOLYSIS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; UBIQUITINATION;

EID: 84896698522     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.01.013     Document Type: Article

References (46)

1. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
2. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
3. Bohrer L.R., Liu P., Zhong J., Pan Y., Angstman J., Brand L.J., Dehm S.M., Huang H. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 2013, 73:1017-1027.
4. Cai C., Chen S., Ng P., Bubley G.J., Nelson P.S., Mostaghel E.A., Marck B., Matsumoto A.M., Simon N.I., Wang H., et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011, 71:6503-6513.
5. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
6. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Saad F., et al. Abiraterone and increased survival in metastatic prostate cancer. N.Engl. J. Med. 2011, 364:1995-2005. COU-AA-301 Investigators.
7. Dehm S.M., Tindall D.J. Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 2011, 18:R183-R196.
8. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
9. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
10. Geng C., He B., Xu L., Barbieri C.E., Eedunuri V.K., Chew S.A., Zimmermann M., Bond R., Shou J., Li C., et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA 2013, 110:6997-7002.
11. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
12. Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J.Natl. Cancer Inst. 2001, 93:1687-1697.
13. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., Melamed J., Tepper C.G., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69:2305-2313.
14. He B., Bai S., Hnat A.T., Kalman R.I., Minges J.T., Patterson C., Wilson E.M. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J.Biol. Chem. 2004, 279:30643-30653.
15. Hernández-Muñoz I., Lund A.H., van der Stoop P., Boutsma E., Muijrers I., Verhoeven E., Nusinow D.A., Panning B., Marahrens Y., van Lohuizen M. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl. Acad. Sci. USA 2005, 102:7635-7640.
16. Hörnberg E., Ylitalo E.B., Crnalic S., Antti H., Stattin P., Widmark A., Bergh A., Wikström P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011, 6:e19059.
17. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22.
18. Hu R., Lu C., Mostaghel E.A., Yegnasubramanian S., Gurel M., Tannahill C., Edwards J., Isaacs W.B., Nelson P.S., Bluemn E., et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012, 72:3457-3462.
19. Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M., Tindall D.J. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. USA 2005, 102:1649-1654.
20. Huang H., Regan K.M., Lou Z., Chen J., Tindall D.J. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 2006, 314:294-297.
21. Kan Z., Jaiswal B.S., Stinson J., Janakiraman V., Bhatt D., Stern H.M., Yue P., Haverty P.M., Bourgon R., Zheng J., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
22. Kim M.S., Je E.M., Oh J.E., Yoo N.J., Lee S.H. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers. APMIS 2013, 121:626-633.
23. Krongrad A., Wilson C.M., Wilson J.D., Allman D.R., McPhaul M.J. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol. Cell. Endocrinol. 1991, 76:79-88.
24. Kumar M.V., Jones E.A., Grossmann M.E., Blexrud M.D., Tindall D.J. Identification and characterization of a suppressor element in the 5'-flanking region of the mouse androgen receptor gene. Nucleic Acids Res. 1994, 22:3693-3698.
25. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
26. Kwon J.E., La M., Oh K.H., Oh Y.M., Kim G.R., Seol J.H., Baek S.H., Chiba T., Tanaka K., Bang O.S., et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J.Biol. Chem. 2006, 281:12664-12672.
27. Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., O'Malley B.W. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30:4350-4364.
28. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K.A., Dehm S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013, 73:483-489.
29. Lin H.K., Wang L., Hu Y.C., Altuwaijri S., Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 2002, 21:4037-4048.
30. Liu P., Li S., Gan L., Kao T.P., Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res. 2008, 68:10290-10299.
31. Liu J., Ghanim M., Xue L., Brown C.D., Iossifov I., Angeletti C., Hua S., Nègre N., Ludwig M., Stricker T., et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009, 323:1218-1222.
32. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
33. Qi J., Tripathi M., Mishra R., Sahgal N., Fazli L., Ettinger S., Placzek W.J., Claps G., Chung L.W., Bowtell D., et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 2013, 23:332-346.
34. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J.Clin. Oncol. 2005, 23:8253-8261.
35. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., de Wit R., Mulders P., Chi K.N., Shore N.D., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N.Engl. J. Med. 2012, 367:1187-1197. AFFIRM Investigators.
36. Sun S., Sprenger C.C., Vessella R.L., Haugk K., Soriano K., Mostaghel E.A., Page S.T., Coleman I.M., Nguyen H.M., Sun H., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J.Clin. Invest. 2010, 120:2715-2730.
37. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
38. van der Steen T., Tindall D.J., Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int. J. Mol. Sci. 2013, 14:14833-14859.
39. Wang L., Zeng X., Chen S., Ding L., Zhong J., Zhao J.C., Wang L., Sarver A., Koller A., Zhi J., et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J. 2013, 32:1584-1597.
40. Watson P.A., Chen Y.F., Balbas M.D., Wongvipat J., Socci N.D., Viale A., Kim K., Sawyers C.L. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. USA 2010, 107:16759-16765.
41. Weber H., Bernhardt A., Dieterle M., Hano P., Mutlu A., Estelle M., Genschik P., Hellmann H. Arabidopsis AtCUL3a and AtCUL3b form complexes with members of the BTB/POZ-MATH protein family. Plant Physiol. 2005, 137:83-93.
42. Xu K., Shimelis H., Linn D.E., Jiang R., Yang X., Sun F., Guo Z., Chen H., Li W., Chen H., et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009, 15:270-282.
43. Zegarra-Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002, 62:1008-1013.
44. Zhang Q., Zhang L., Wang B., Ou C.Y., Chien C.T., Jiang J. A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev. Cell 2006, 10:719-729.
45. Zhou H.J., Yan J., Luo W., Ayala G., Lin S.H., Erdem H., Ittmann M., Tsai S.Y., Tsai M.J. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005, 65:7976-7983.
46. Zhuang M., Calabrese M.F., Liu J., Waddell M.B., Nourse A., Hammel M., Miller D.J., Walden H., Duda D.M., Seyedin S.N., et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 2009, 36:39-50.